【藥品性質提示】 #本品不得與含鈣溶液混合，會造成沉澱，如同一管路先後使用，必須徹底沖洗。

Acute otitis media; Bacterial meningitis; Gonorrhea; Infection of bone - Infectious disorder of joint; Infection of skin and/or subcutaneous tissue; Infectious disease of abdomen; Lower respiratory tract infection; Pelvic inflammatory disease; Postoperative infection; Prophylaxis; Sepsis; Urinary tract infectious disease.

Antibiotic, Cephalosporin (Third Generation)
Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis.

1.Absorption: IM: Well absorbed.
2.Distribution: Widely throughout the body including gallbladder, lungs, bone, bile, CSF (higher concentrations achieved when meninges are inflamed); Vd: Adults: ~6 to 14 L.
3.Protein binding: 85% to 95%.
4.Half-life elimination: Adults: Normal renal and hepatic function: ~5 to 9 hours.
5.Excretion: Urine (33% to 67% as unchanged drug); feces (as inactive drug).

Hypersensitivity to ceftriaxone, any component of the formulation, or other cephalosporins; do not use in hyperbilirubinemic neonates.

Ceftriaxone crosses the placenta.

Ceftriaxone is present in breast milk.

1.Dermatologic: Skin tightness (IM; local), Skin rash (2%)
2.Local: Induration at injection site (incidence higher with IM), warm sensation at injection site (IM)
3.Gastrointestinal: Diarrhea (3%)
4.Hematologic & oncologic: Eosinophilia (6%), leukopenia (2%), thrombocytosis (5%)
5.Hepatic: Increased serum alanine aminotransferase (3%), increased serum aspartate aminotransferase (3%)
6.Renal: Increased blood urea nitrogen (1%)

1.Bloodstream infection: IV: 2 g once daily . For patients with pneumococcal bacteremia, administer 2 g every 12 hours in combination with vancomycin until meningitis is ruled out.
2.Intra-abdominal infection, mild to moderate:
(1)Cholecystitis, acute: IV: 1 to 2 g once daily; continue for 1 day after gallbladder removal or until clinical resolution in patients managed nonoperatively.
(2)Other intra-abdominal infections (eg, appendicitis, diverticulitis, intra-abdominal abscess): IV: 1 to 2 g once daily in combination with metronidazole.
3.Meningitis, bacterial: IV: 2 g every 12 hours.
4.Otitis media, acute : IM, IV: 1 to 2 g once daily for 3 days .
5.Skin and soft tissue infection: IV: 1 to 2 g once daily, usually as part of an appropriate combination regimen.
6.Urinary tract infection, complicated:
(1)Inpatients: IV: 1 g once daily.
(2)Outpatients: IV, IM: 1 g once, followed by 5 to 14 days of appropriate oral therapy.

General dosing:
IM, IV: 50 to 75 mg/kg/day in divided doses every 12 to 24 hours; maximum daily dose: 2,000 mg/day; higher doses are recommended in certain infections (eg, endocarditis, meningitis)

1. CrCl >15 mL/minute: No dosage adjustment necessary.
2. CrCl <15 mL/minute: No dosage adjustment necessary. Use of >2 g/day has not been studied and should be done with close monitoring, especially in patients with concurrent hepatic dysfunction.
3. Hemodialysis, Peritoneal dialysis: Poorly dialyzed; no dosage adjustment necessary.
4. CRRT, PIRRT: No dosage adjustment necessary.

No adjustment is necessary in patients with hepatic impairment.In patients with both hepatic dysfunction and significant renal disease, maximum dosage is 2 g/day.